Laboratory Tested

Science is based on a method that constantly tests every theory, technology, medicine, or development. If it repeatedly demonstrates its validity, its effectiveness is established and legitimized.

Our technology has been studied in various national and international laboratories, where its effectiveness has been proven. This was primarily driven by the SARS-CoV-2 pandemic and the interest of several countries in developing products containing this active ingredient.

Below are some of the first institutions that validated and endorsed the effectiveness of our Nano-Bio-Technology and a list of studies that prove the effectiveness of the technology used in Éviter and Eion products.

National Institute of Respiratory Diseases.

INER houses Mexico's most important virology and microbiology laboratory, responsible, among other things, for identifying the A-H1N1 virus strain during the 2009 pandemic. This led to the development of the vaccine. In this same laboratory, the inhibitory effect of the nanobiomolecule, the active ingredient in Eviter, on influenza A-H1N1 virus infection in MDCK cells was demonstrated.

National Polytechnic Institute.

In his immunochemistry laboratory, it was studied in an antimicrobial assay, concluding that it inhibited 99% of the tuberculous and non-tuberculous mycobacteria tested.

Autonomous University of Nuevo León.

At the Faculty of Chemical Sciences / Food, Medicine and Toxicology Laboratory, different types of strains (bacteria, viruses, spores, mycobacteria, etc.) were analyzed, verifying the antimicrobial effectiveness of the Nano Bio Molecule, as well as its Biodegradability and harmlessness (it does not damage cells).

 

November 20 Hospital.

In its Genomic Medicine division, it was demonstrated that human DNA that came into contact with the NanoBioMolecule suspension at different times and concentrations did not show any degradation, proving that the NanoBioTechnology used in Éviter® is completely safe to use.

 

 

1. Classification of ingredient with CAS number American Chemical Society.
2. National Institute of Medical Sciences and Nutrition Salvador Zubirán. Antimicrobial activity of Éviter.
3. UANL Autonomous University of Nuevo León. Biodegradability.
4. UANL Autonomous University of Nuevo León. No irritability.
5. LabTox Laboratory. Department of Reproductive Biology and Toxicology, Institute of Sciences (ICUAP). Acute dermal protocol.
6. Industrial Microbiological Laboratory MICROMEX, SA de CV.  Pathogen Analysis in Hands and Nails.
7. Lloydmex Laboratories. Microbial Effectiveness Food Industry.
8. UANL Autonomous University of Nuevo León. Sanitizing antimicrobial activity.
9. CEICALab. Escherichia coli, staphylococcus aureus microbial challenge .
10. CEICALab. Germicidal Report.
11. UANL Autonomous University of Nuevo León. Antimicrobial activity of toothpaste.
12. UANL Autonomous University of Nuevo León. Antimicrobial activity mouthwash.
13. UANL Autonomous University of Nuevo León. Sanitizing antimicrobial activity for direct use.
14. UANL Autonomous University of Nuevo León. Biodegradability Sanitizer for direct use .
15. Guerrero Mother and Child Hospital. Certificate of Residual Sanitizer for Direct Use .
16. ACCUGEN Laboratory, USA. 3rd FDA. Staphylococcus Aureus Test the germicidal and detergent sanitizing action of disinfectants.
17. ACCUGEN Laboratory, USA. 3rd FDA.  Ps Aeruginosa Germicidal action and sanitizing detergent assay of disinfectants.
18. ACCUGEN Laboratory, USA. 3rd FDA. Salmonella Enterica Test germicidal action and sanitizing detergent for disinfectants.
19. ACCUGEN Laboratory, USA 3rd FDA Study. Clostridium difficile and clostridium sporagens.
20. ACCUGEN Laboratories USA. 3rd FDA. In vitro Cytotoxicity: direct use sanitizer.
21. ACCUGEN Laboratories USA. 3rd FDA. Corrosiveness: direct use sanitizer.
22. Faculty of Veterinary Medicine and Animal Husbandry, UNAM. Evaluation of direct-use sanitizer Escherichia coli.
23. L. Pasteur Microbiology, SA de CV. Microbial Challenge: direct use sanitizer.
24. High Specialty Naval General Hospital. Disinfection with direct-use sanitizer. On-site testing.
25. Fray Antonio Mayor Civil Hospital, Guadalajara, Mexico. Disinfection with direct-use sanitizer. On-site testing.
26. Valentin Gomez Farías Hospital. Disinfection with direct-use sanitizer. On-site testing.
27. ISSSTE. Western Regional Delegation. Disinfection with direct-use sanitizer. On-site testing.
28. Study to determine the effectiveness of Éviter active nanoparticulate in two second-level hospitals.
29. Torreón General Hospital, Coahuila. Éviter Effectiveness. Disinfection with direct-use sanitizer. On-site testing.
30. UMAE H. Pediatrics CMN 21st Century. Avoiding Effectiveness. Disinfection with direct-use sanitizer. On-site testing.
31. Spanish Charity of Laguna Torreón, Coahuila. Effectiveness Avoid. Disinfection with direct-use sanitizer. On-site testing.
32. Acapulco General Hospital. Disinfection with direct-use sanitizer. On-site testing.
33. November 20 Hospital. Disinfection with direct-use sanitizer. On-site testing.
34. GEA González Hospital. Disinfection with direct-use sanitizer. On-site testing.
35. Nicolás San Juan Hospital, State of Mexico. Disinfection with direct-use sanitizer. On-site testing.
36. Specialized Hospital of the State of Mexico for Visual Health. Éviter effectiveness in operating rooms.
37. General Hospital of Zone No. 33, IMSS Nuevo León. Disinfection with direct-use sanitizer. On-site testing.
38. Midwestern University. “Mechanism of Action of TIO2 Nanoparticles, Functionalized with Flavonoids and Terpenes SARS-CoV2”.
39. INER National Institute of Respiratory Diseases. “Coronavirus 229E Inhibitory Effect”.
40. Nbelyax. “Inhibition of the SARS-CoV-2 Coronavirus.”
41. INER National Institute of Respiratory Diseases. “H1N1 Influenza Coronavirus Effect”.
42. INCMNSSZ National Institute of Medical Sciences and Nutrition Salvador Zubirán. “Infection letter”.
43. IPN National Polytechnic Institute. “Study on the anti-mycobacterial activity of Nbeylax”.
44. NW Laboratory Switzerland. “Nbelyax Antibacterial effect”.
45. INER National Institute of Respiratory Diseases. “Nbelyax VHS, VSR, Candida and A. fumigatus.”
46. IPN National Polytechnic Institute Immunochemical Laboratory II “ Mycobacteria Certificate” .
47. UANL Autonomous University of Nuevo León. “ Sporicidal Activity.”
48. Laboratory Control, Spain. “ Bacteriological activity for general disinfection according to UNE-EN 1276.”
49. COPARMEX. 2016 National Health Award. Private Institution Category.
50. Ministry of Health – INER – World Health Organization Certificate.
51. UAP Autonomous University of Puebla.  “Oral administration toxicity study in animals Nbelyax 90 days”.
52. UAP Autonomous University of Puebla. “ Nbelyax animals oral administration repeated doses 365 days.”
53. UAP Autonomous University of Puebla. “ Nbelyax in vivo micronucleus assay.”
54. INER National Institute of Respiratory Diseases. “Cytotoxic effect”.
55. ECORFAN Journal. “ Effects of administering TiO2 nanoparticles functionalized with Nbeylax on the DNA of cancer cells.”
56. ACCUGEN Laboratory. USA. 3rd FDA Study. “In vitro cytotoxicity”.
57. ACCUGEN Laboratory. USA. 3rd FDA Study. “ Corrositex Corrosiveness”.
58. NORMPEX EPA 796 3200. “Biodegradability”.
59. ISSSTE National Medical Center. “ Genomic Medicine.”
60. Safety Product Laboratory. “ Skin sensitization test in guinea pigs – Buehler method.”
61. Safety Product Laboratory. “Primary eye irritation in rabbits.”